[{"orgOrder":0,"company":"Sciwind","sponsor":"IDG Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences to Present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
XW003 is a novel, biased long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing.
Sciwind plans to use the proceeds to advance clinical development of its proprietary GLP-1 receptor agonism candidates and anticipates the development milestones from the three lead programs: XW003, XW004 and XW014.